1. Home
  2. CCEL vs NSRX Comparison

CCEL vs NSRX Comparison

Compare CCEL & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cryo-Cell International Inc.

CCEL

Cryo-Cell International Inc.

HOLD

Current Price

$3.46

Market Cap

27.8M

Sector

Health Care

ML Signal

HOLD

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$3.02

Market Cap

32.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCEL
NSRX
Founded
1989
2019
Country
United States
Israel
Employees
N/A
7
Industry
Managed Health Care
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.8M
32.2M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
CCEL
NSRX
Price
$3.46
$3.02
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
N/A
$19.67
AVG Volume (30 Days)
7.5K
79.9K
Earning Date
04-14-2026
03-25-2026
Dividend Yield
4.26%
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$25,384,279.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$344.00
N/A
Revenue Growth
9.76
N/A
52 Week Low
$2.72
$1.98
52 Week High
$5.52
$9.99

Technical Indicators

Market Signals
Indicator
CCEL
NSRX
Relative Strength Index (RSI) 46.48 49.88
Support Level $3.18 $2.04
Resistance Level $3.57 $3.48
Average True Range (ATR) 0.19 0.25
MACD -0.02 -0.01
Stochastic Oscillator 6.12 34.88

Price Performance

Historical Comparison
CCEL
NSRX

About CCEL Cryo-Cell International Inc.

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: